Showing results (21-30 of 80) with videos related to

Sort By:
Pageof 8
Advanced Materials (Deerfield Beach, Fla.)|March 19, 2020
2D MXene-TiO2 Core-Shell Nanosheets as a Data-Storage Medium in Memory DevicesBenzheng Lyu, Yongsuk Choi, Hongyue Jing, et al.
AJR. American Journal of Roentgenology|May 23, 2015
FDG PET/CT for Management and Assessing Outcomes of Squamous Cell Cancer of the Oral CavityMohammed A Pasha, Charles Marcus, Carole Fakhry, et al.
The American Journal of Surgical Pathology|April 24, 2018
Salivary Secretory Carcinoma With a Novel ETV6-MET Fusion: Expanding the Molecular Spectrum of a Recently Described EntityLisa M Rooper, Theodoros Karantanos, Yi Ning, et al.
AJR. American Journal of Roentgenology|March 22, 2016
FDG PET/CT in Patients With Head and Neck Squamous Cell Carcinoma After Primary Surgical Resection With or Without Chemoradiation TherapyMehdi Taghipour, Sara Sheikhbahaei, Rick Wray, et al.
Head & Neck|November 14, 2018
Pattern of planned systemic therapy usage in newly diagnosed, nonmetastatic squamous cell carcinoma of the head and neck in a commercially insured population in the United StatesJong Chul Park, Christine G Gourin, Ana P Kiess, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2016
Whole-Exome Sequencing of Salivary Gland Mucoepidermoid CarcinomaHyunseok Kang, Marietta Tan, Justin A Bishop, et al.
Molecular Cancer Therapeutics|May 5, 2026
Potent anti-tumor activity of the AXL-targeted antibody-drug conjugate, mipasetamab uzoptirine (ADCT-601), in preclinical models of adenoid cystic carcinomaJoseph O Humtsoe, Leilani Jones, Anita Pothukuchi, et al.
Molecular Cancer Therapeutics|May 25, 2026
Potent Anti-Tumor Activity of the AXL-Targeted Antibody-Drug Conjugate, Mipasetamab Uzoptirine (ADCT-601), in Preclinical Models of Adenoid Cystic CarcinomaJoseph O Humtsoe, Leilani Jones, Anita Pothukuchi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2021
Treatment of Fanconi Anemia-Associated Head and Neck Cancer: Opportunities to Improve OutcomesRex H Lee, Hyunseok Kang, Sue S Yom, et al.
The Oncologist|October 10, 2018
Clinical Benefit to an Aurora A Kinase Inhibitor in a Patient with Metastatic Integrase Interactor 1-Deficient CarcinomaTheodoros Karantanos, Lisa Rooper, Youme Kang, et al.
Pageof 8